Skip to main content
Midas Edge

Theravance Biopharma, Inc.

For the period ended Dec 31, 2025. Filed Mar 23, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 23, 2026

TBPH$17.030.0%Stored close · as of Sep 23, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​THERAVANCE BIOPHARMA, INC.​
Date: March 23, 2026By:/s/ Rick E Winningham
​​Rick E Winningham
​​Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Rick E Winningham as their true and lawful attorney-in-fact and agent, each with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to the annual report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

​​​​​​​​​​
​Signature​​​​Title​​​​Date​
​​​
/s/ Rick E WinninghamRick E WinninghamChief Executive Officer (Principal Executive Officer)March 23, 2026
​​​
/s/ Aziz SawafAziz SawafSenior Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)March 23, 2026
​/s/ Laurie S. Alsup, M.D.Laurie S. Alsup, M.D.DirectorMarch 23, 2026
​/s/ Eran BroshyEran BroshyDirectorMarch 23, 2026
​/s/ Jeremy T. GrantJeremy T. GrantDirectorMarch 23, 2026
​/s/ Susannah GraySusannah GrayChairperson of the Board of DirectorsMarch 23, 2026
​​​​​​​​​​
​Signature​​​​Title​​​​Date​
​/s/ Jim KellyJim KellyDirectorMarch 23, 2026
​​​
/s/ Dean J. MitchellDean J. MitchellDirectorMarch 23, 2026
​/s/ Donal O’ConnorDonal O’ConnorDirectorMarch 23, 2026
​/s/ Deepika R. Pakianathan, Ph.D.Deepika R. Pakianathan, Ph.D.DirectorMarch 23, 2026
​​​

F

Theravance Biopharma, Inc.

Index to Consolidated Financial Statements

Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)​ ​ ​F-2
Consolidated Balance Sheets as of December 31, 2025 and 2024​F-4
Consolidated Statements of Operations for each of the two years in the period ended December 31, 2025​F-5
Consolidated Statements of Comprehensive Income (Loss) for each of the two years in the period ended December 31, 2025​F-6
Consolidated Statements of Shareholders’ Equity for each of the two years in the period ended December 31, 2025​F-7
Consolidated Statements of Cash Flows for each of the two years in the period ended December 31, 2025​F-8
Notes to Consolidated Financial Statements​F-9
Supplementary Financial Data (unaudited)​F-39
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.